Publication: Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Kaymaz-Tahra, Sema
Tsechelidis, Ozun Bayindir
Ince, Burak
Ozdemir-Isik, Ozlem
Kutu, Muhammet Emin
Karakas, Ozlem
Demirci-Yildirim, Tuba
Ademoglu, Zeliha
Ediboglu, Elif
Uludogan, Burcu Ceren
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to assess the characteristics of TAK patients needed biologic treatment during follow-up in daily practice.
Source
Publisher
Wiley
Subject
Citation
item.page.haspartof
Source
Arthritis and Rheumatology
item.page.ispartofseries
item.page.edition
DOI
10.1136/annrheumdis-2025-eular.a1618
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A